Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donepezil in Down syndrome with regression symptoms and impaired activities of daily living
2018-003426-89Phase 2
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Down syndrome comparing Donepezil (E2020) with Placebo (2 arms). Primary endpoint: Change from baseline in Body Functionality Checklist total score at Week 24 vs placebo.
02
Drugs
donepezil
03
Conditions
Down syndrome
Beyond the preview
Go deeper on 2018-003426-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003426-89.